The short answer
Ozempic and Wegovy are not the same medication, even though both contain semaglutide. Ozempic is an injection approved for type 2 diabetes and related cardiovascular and kidney risk reduction. Wegovy, available as Wegovy injection and WEGOVY (semaglutide) tablets, is approved for chronic weight management and cardiovascular risk reduction in people with heart disease and obesity or overweight. Rybelsus is a tablet approved for type 2 diabetes and, since 2025, cardiovascular risk reduction in high-risk type 2 diabetes. The current Rybelsus label also covers a product named OZEMPIC tablets with the same indications; it is not the same as Ozempic injection.
Boxed warning shared by all semaglutide products
Semaglutide caused thyroid C-cell tumors in rodents; human relevance is unknown. These products are contraindicated with a personal or family history of medullary thyroid carcinoma or with MEN 2.
Labels also warn about pancreatitis, gallbladder disease, low blood sugar when combined with insulin or sulfonylureas, kidney injury from dehydration, and diabetic retinopathy complications in people with diabetes. Compounded semaglutide is not FDA approved and is not equivalent to these products.
Current label check
The medication-specific claims on this page were checked against these current product labels on 2026-10-03.
| Product label | Label date | Boxed warning on that label |
|---|---|---|
| Ozempic (semaglutide) injection | 2026-06-01 | Thyroid C-cell tumors |
| Wegovy (semaglutide) injection and tablets | 2026-06-18 | Thyroid C-cell tumors |
| Rybelsus and Ozempic (semaglutide) tablets | 2026-01-30 | Thyroid C-cell tumors |
Established evidence
Side-by-side comparison
Indications below summarize current U.S. labeling; check the full label for details and age criteria.
| Feature | Ozempic | Wegovy | Rybelsus |
|---|---|---|---|
| Form | Weekly injection | Weekly injection or daily tablet | Daily tablet |
| Main approved use | Type 2 diabetes glycemic control (adults) | Chronic weight management (injection: adults and children 12 and older meeting criteria) | Type 2 diabetes glycemic control (adults) |
| Cardiovascular indication | In type 2 diabetes with heart disease | In established heart disease with obesity or overweight | In type 2 diabetes at high cardiovascular risk (added 2025) |
| Other indications | Kidney disease risk reduction in type 2 diabetes with chronic kidney disease | Injection: MASH with moderate to advanced fibrosis | None for weight |
| Approved for weight loss? | No | Yes | No |
Why the same ingredient can be different medicines
The FDA approves products, not molecules in general. Each approval rests on trials in a specific population with a specific dose range and form. Wegovy reaches higher maintenance doses than Ozempic and was studied in people with obesity; Ozempic was studied in type 2 diabetes. Insurance plans also cover by indication, so a plan may cover Ozempic for diabetes but not Wegovy for weight management, or the reverse.
Wegovy tablets vs Rybelsus
Both are daily semaglutide tablets that must be taken on an empty stomach with a small amount of water and a wait before eating. They are approved for different conditions and use different strengths, so one is not a substitute for the other. Foundayo (orforglipron) is a different oral GLP-1 that is a small molecule rather than a peptide; see the Foundayo guide for its labeling.
Established evidence
Common side effects
- Nausea, vomiting, diarrhea, constipation, abdominal pain
- Fatigue and headache
- Most gastrointestinal effects are worst during dose increases
Are GLP-1s menopause medications?
No. They treat obesity, type 2 diabetes, and related cardiometabolic risks. Midlife weight change is common, and GLP-1 medicines may be part of care for people who meet criteria, but they do not treat hot flashes or replace hormone therapy.
Questions to ask a healthcare professional
- Which product matches my diagnosis and coverage?
- Is an injection or a tablet more realistic for me?
- How do we limit muscle loss during weight loss?
Questions, answered
What people ask about Ozempic; Wegovy; Rybelsus
Are Ozempic and Wegovy the same?+
No. They share the active ingredient semaglutide but are separate products with different FDA indications and dose ranges.
Is Ozempic approved for weight loss?+
No. Ozempic is approved for type 2 diabetes and related cardiovascular and kidney risk reduction. Wegovy is the semaglutide product approved for weight management.
Is there a Wegovy pill?+
Yes. The FDA-approved product name is WEGOVY (semaglutide) tablets, approved in December 2025 for chronic weight management and cardiovascular risk reduction in eligible adults. It is a daily oral tablet, distinct from Rybelsus.
Is compounded semaglutide the same as Wegovy?+
No. Compounded drugs are not FDA approved and are not reviewed by the FDA for safety, effectiveness, or quality.
Kindr Health does not claim to offer Ozempic; Wegovy; Rybelsus on this page. Availability and prescribing are not implied.
A broader care pathway
Explore metabolic health care
Learn how Kindr Health care pathways work. Any treatment decision is made by a licensed professional; a prescription is never guaranteed.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- WEGOVY (semaglutide) injection and tablets prescribing information (2026) — U.S. Food and Drug Administration. www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256Orig1s029,%20218316Orig1s005lbl.pdf
- Wegovy (semaglutide) tablets NDA approval letter (2025) — U.S. Food and Drug Administration. www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218316Orig1s000ltr.pdf
- Ozempic prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ozempic
- Rybelsus prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rybelsus
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.